Results of combined treatment of anaplastic thyroid carcinoma (ATC)

Autor: Jean-Louis Peix, Céline Segura-Ferlay, Claire Bournaud, Jean-Christophe Lifante, Christelle de la Fouchardière, Sami Limem, Olfa Derbel, Jean-Pierre Droz, Françoise Borson-Chazot, Christian Carrie
Přispěvatelé: Centre Léon Bérard [Lyon], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Référence Maladie Rare 'Syndromes neurologiques Paranéoplasiques', Hospices Civils de Lyon (HCL)-Hopital Neurologique, Service d'Oncologie Médicale [Centre hospitalier Lyon Sud - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)
Jazyk: angličtina
Rok vydání: 2011
Předmět:
Male
Cancer Research
MESH: Remission Induction
MESH: Combined Modality Therapy
medicine.medical_treatment
Thyroid Carcinoma
Anaplastic
Institut Gustave Roussy
0302 clinical medicine
MESH: Aged
80 and over
Antineoplastic Combined Chemotherapy Protocols
MESH: Dose Fractionation
Medicine
Aged
80 and over
MESH: Aged
0303 health sciences
MESH: Middle Aged
Remission Induction
Mediastinum
Middle Aged
Prognosis
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Combined Modality Therapy
3. Good health
MESH: Antineoplastic Combined Chemotherapy Protocols
medicine.anatomical_structure
Oncology
MESH: Thyroid Neoplasms
030220 oncology & carcinogenesis
MESH: Survival Analysis
Thyroidectomy
Female
France
Research Article
Adult
medicine.medical_specialty
[SDV.CAN]Life Sciences [q-bio]/Cancer
lcsh:RC254-282
MESH: Prognosis
MESH: Thyroidectomy
Thyroid carcinoma
03 medical and health sciences
MESH: Doxorubicin
Genetics
Humans
Thyroid Neoplasms
Survival analysis
030304 developmental biology
Aged
Retrospective Studies
MESH: Humans
business.industry
Dose fractionation
MESH: Adult
MESH: Retrospective Studies
medicine.disease
Survival Analysis
MESH: Male
Surgery
MESH: France
MESH: Cisplatin
Doxorubicin
Dose Fractionation
Radiation
Cisplatin
business
MESH: Female
Progressive disease
Zdroj: BMC Cancer
BMC Cancer, BioMed Central, 2011, 11, pp.469. ⟨10.1186/1471-2407-11-469⟩
BMC Cancer, Vol 11, Iss 1, p 469 (2011)
ISSN: 1471-2407
DOI: 10.1186/1471-2407-11-469⟩
Popis: Background Anaplastic thyroid carcinoma (ATC) is among the most aggressive human malignancies. It is associated with a high rate of local recurrence and with poor prognosis. Methods We retrospectively reviewed 44 consecutive patients treated between 1996 and 2010 at Leon Berard Cancer Centre, Lyon, France. The combined treatment strategy derived from the one developed at the Institut Gustave Roussy included total thyroidectomy and cervical lymph-node dissection, when feasible, combined with 2 cycles of doxorubicin (60 mg/m2) and cisplatin (100 mg/m2) Q3W, hyperfractionated (1.2 Gy twice daily) radiation to the neck and upper mediastinum (46-50 Gy), and then four cycles of doxorubicin-cisplatin. Results Thirty-five patients received the three-phase combined treatment. Complete response after treatment was achieved in 14/44 patients (31.8%). Eight patients had a partial response (18.2%). Twenty-two (50%) had progressive disease. All patients with metastases at diagnosis died shortly afterwards. Thirteen patients are still alive. The median survival of the entire population was 8 months. Conclusion Despite the ultimately dismal prognosis of ATC, multimodality treatment significantly improves local control and appears to afford long-term survival in some patients. There is active ongoing research, and results obtained with new targeted systemic treatment appear encouraging.
Databáze: OpenAIRE
Externí odkaz: